Clinical trials of combination of CB-839 with various therapeutic agents are ongoing in patients with renal cell carcinomas (RCC), melanoma, or non-small cell lung cancer (https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/glutaminase-inhibitor-cb-839). This evidence concerns the gene GLS and hereditary clear cell renal cell carcinoma.